[This is a document template that you can use to ensure that your paper can be read and typeset with ease:

* Heading levels and text layout have been prepared for you.
* The red text explains each element.
* You will need to delete the red text and/or replace the text with required details prior to submitting your paper.
* For typesetting it is preferable if you prepare your manuscript using Styles, eg. Heading 1, Normal, etc.]

[Paper type. Please choose one from [list](https://www.dovepress.com/author-guidelines/article-types) on our website]

[First author] et al

# Manuscript title

Author name [Please list all authors here and do not include abbreviated qualifications]1

Author name2

1Author affiliations [list all author affiliations in the form of department, institution, city, state, country]; 2Author affiliations

If 2 or more authors on a paper contributed equally, please use the following format:

Author name1\*  
Author name2\*  
Author name3   
\*These authors contributed equally to this work

Correspondence: [Full name of corresponding author.]

[Include full postal address here (please include institution).]

Tel (optional) [Full international phone number, eg, +1 404 234 5433]

Fax (optional) [Full international fax number.]

Email (mandatory)

**Abstract:** [There are two types of abstract. One is structured and the other is not. Both should be no more than 300 words. Unstructured abstracts should be given in one paragraph and outline the purpose of the paper, results obtained, and conclusions. Review articles commonly have unstructured abstracts. Original research articles commonly have a structure as follows in the below example].

**Purpose:**

**Patients and methods:**

**Results:**

**Conclusion:**

**Keywords:** [Choose four to six keywords. They should not repeat words given in the title.]

# Introduction

[This is an example of text formatting. Please note that citations are in superscript numerals following the punctuation. Abbreviations are defined in full at their first instance.]

Subdermal contraceptive implants have been studied and used in humans for over twenty years.1,2 Contraceptive implants provide long-acting, highly effective reversible contraception. The most recently introduced subdermal implant, Implanon® (N.V. Organon, Oss, the Netherlands), also referred to as the etonogestrel (ENG) implant, is a single rod implant that offers three years of contraceptive efficacy.3–6 The ENG implant has been used in more than 30 countries, including Australia, Indonesia, and the Netherlands, and was approved by the United States Food and Drug Administration (FDA) in 2006. The ENG implant is an excellent option for women with contraindications to estrogen in addition to any woman who desires long-acting reversible contraception.

The ENG implant is a single rod implant measuring 40 mm long and 2 mm in diameter with a solid core of ethylene vinyl acetate (EVA) impregnated with 68 mg of etonogestrel, the biologically active metabolite of desogestrel.7,8 The EVA copolymer allows controlled release of hormone over three years of use.9 Each implant is provided in a disposable sterile inserter for subdermal application.

[Generally each major section of your manuscript should have a heading. The most common breakdown of a paper is given below, with some subheadings related to the above example text. Please delete or include as needed.]

# Material and methods

## Etonogestrel implant [This is an example of a level 2 heading.]

### Efficacy [This is an example of a level 3 heading.]

# Results

# Discussion

# Conclusion

# Acknowledgments

# Disclosure

The author(s) report no conflicts of interest in this work. [Each manuscript needs to include a disclosure of financial interest or other conflict of interest statement. This is where these statements go].

# References

[The following are examples of our reference style. Please see [Reference Style Guidelines](https://www.dovepress.com/author-guidelines/reference-stylesheet) for more details.]

1. Burnier M, Fricker AF, Hayoz D, et al. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. *Eur J Clin Pharmacol*. 1999;55:633–637.
2. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. *Am J Med*. 2001;110:582–584.
3. Fried LF, Palevsky PM. Hyponatremia and hypernatremia. *Med Clin North Am*. 1997;81:585–609.
4. [Gheorghiade M](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Gheorghiade%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Konstam MA](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Konstam%20MA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Burnett JC Jr](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Burnett%20JC%20Jr%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), et al; [Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Efficacy%20of%20Vasopressin%20Antagonism%20in%20Heart%20Failure%20Outcome%20Study%20With%20Tolvaptan%20(EVEREST)%20Investigators%22%5BCorporate%20Author%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus). Short term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. *JAMA*. 2007;297:1332–1343.
5. Vaprisol (conivaptan HCl injection) [package insert]. Deerfield IL: Astellas Tokai Co.; February 2006.

**Table 1** [Table titles do not end with a full stop.]

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**Notes:**

**Abbreviations:** AUC, area under the curve; LS, least squares; NE, not estimable. [These are examples of format.]

**Figure 1** [Title of figure and ends in a full stop. Please see [Figures and tables](https://www.dovepress.com/author-guidelines/figures-tables) for our Figure requirements.]